Literature DB >> 8957672

Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes.

G F Arnold1, D A Resnick, A D Smith, S C Geisler, A K Holmes, E Arnold.   

Abstract

Chimeric human rhinoviruses (HRVs) have the potential to serve as vaccines against a wide variety of diseases. Such vaccines can be developed optimally by generating libraries of chimeric HRVs displaying immunogens from dangerous pathogens or tumor cells in many different conformations. Extremely large numbers of conformationally defined presentations of foreign epitopes can be produced efficiently by flanking transplanted epitopes with linkers, or adapters, of small segments of randomized amino acids. In addition, the individual residues of the immunogenic sequences can be encoded in proportion to their prevalence in databases, generating composite immunogens that function as mimotopes. The diversity of sequences and conformations improves the likelihood of generating immunologically valuable vaccine candidates. Chimeric viruses thus generated can be propagated and purified to select for viruses whose growth and physical stability are like those of wild-type HRV. Viruses containing a foreign epitope in antigenically relevant conformations can then be captured by immunoselection with neutralizing antibodies directed against the foreign pathogen. Using this approach, we have been able to generate HRV chimeras that present V3 loop sequences of the human immunodeficiency virus type 1 (HIV-1) in immunologically relevant conformations. Antisera directed against such chimeras can neutralize multiple strains of HIV-1 in cell culture, suggesting that the HRV14:HIV-1 chimeras may be presenting their V3 loop sequences in manners that mimic those of multiple strains of HIV. Immunologically interesting chimeras can be examined using X-ray crystallography to yield detailed information about the structures of chimeras with immunogenic epitopes. This information may lead to a greater understanding of key functional and structural elements of immunogenicity. The chimeric HRV system allows one to present virtually any protein epitope or mimitope thereof, identify viruses with immunological characteristics that mimic those of the foreign pathogen, and examine the structures of these immunogenic sequences at the atomic level.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957672     DOI: 10.1159/000150477

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  10 in total

Review 1.  AIDS vaccine development: let a thousand flowers bloom.

Authors:  J S Oxford; M Addawe; R Lambkin
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

Authors:  P A Kratz; B Böttcher; M Nassal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Characterization of replication-competent hepatitis A virus constructs containing insertions at the N terminus of the polyprotein.

Authors:  Y Zhang; G G Kaplan
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites.

Authors:  Andrew T Dufresne; Elena Y Dobrikova; Stacie Schmidt; Matthias Gromeier
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.

Authors:  B S Graham; R C Kines; K S Corbett; J Nicewonger; T R Johnson; M Chen; D LaVigne; J N Roberts; N Cuburu; J T Schiller; C B Buck
Journal:  Mucosal Immunol       Date:  2010-06-16       Impact factor: 7.313

8.  The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine.

Authors:  Kevin D Pavelko; Michael P Bell; Lavakumar Karyampudi; Michael J Hansen; Kathleen S Allen; Keith L Knutson; Larry R Pease
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

9.  HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.

Authors:  Qiana L Matthews; Aiman Fatima; Yizhe Tang; Brian A Perry; Yuko Tsuruta; Svetlana Komarova; Laura Timares; Chunxia Zhao; Natalia Makarova; Anton V Borovjagin; Phoebe L Stewart; Hongju Wu; Jerry L Blackwell; David T Curiel
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

Review 10.  Therapeutic Use of Native and Recombinant Enteroviruses.

Authors:  Jani Ylä-Pelto; Lav Tripathi; Petri Susi
Journal:  Viruses       Date:  2016-02-23       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.